Treasure Island (603567.SH) subsidiary will receive the exclusive sales agency rights for the TRS005, developed independently by Zhejiang Teruisi, in China.

Zh tng cijng APP xn, zhn bo do (603567.SH) fb gnggo, gngs qunz zgngs hilngjing zhn bo do yo yo moy yuxin gngs (jinchng "hi y mo") y zhjing t ru s yoy gfn yuxin gngs (jinchng "zhjing t ru s") qindngle "Yopn zhnggu q jngxio qun l htng", hud zhjing t ru s zxng ynf de TRS005 zi zhnggu dq de xioshu dil qun. Zhtng Caijing APP News, Treasure Island (603567.SH) announced that its wholly-owned subsidiary Heilongjiang Zhenbaodao Medical Trading Co., Ltd. (referred to as "Hei Yimao") has signed a "Drug China Region Distribution Authorization Contract" with Zhejiang Teruisi Pharmaceutical Co., Ltd. (referred to as "Zhejiang Teruisi"), obtaining the exclusive sales agent rights for TRS005, a product developed by Zhejiang Teruisi, in China.